Drug Profile
Salirasib
Alternative Names: KD 032; ONO-7056; S-Farnesylthiosalicyclic acid; Transfarnesylthiosalicyclic acidLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Concordia Pharmaceuticals
- Developer Concordia Pharmaceuticals; Johns Hopkins University; Kadmon Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Ono Pharmaceutical
- Class Antineoplastics; Benzoic acids; Sulfides
- Mechanism of Action MTOR protein inhibitors; Ras protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 31 Oct 2015 Discontinued - Phase-I for Solid tumours in Japan (PO)
- 15 Jun 2015 Discontinued - Phase-I for Colorectal cancer in USA (PO)
- 15 Jun 2015 Discontinued - Phase-I/II for Pancreatic cancer in USA (PO)